The 2024 China International Fair for Trade in Services (CIFTIS) was held from September 12th to 16th at the China National Convention Center in Beijing. CIFTIS is the world's only national, international, and comprehensive platform for trade in services.

The 2024 CIFTIS, themed "Global Services, Mutual Benefits, and Shared Prosperity," was jointly hosted by the Ministry of Commerce and the Beijing Municipal People's Government, with support from international organizations including the World Trade Organization, the United Nations Conference on Trade and Development, and the Organization for Economic Cooperation and Development. It stands as the only comprehensive trade in services exhibition globally that encompasses all 12 sectors of the service trade.

For the first time, Sichuan Province served as the guest province of honor at CIFTIS, establishing a 240-square-meter Sichuan Comprehensive Pavilion to showcase high-quality "Sichuan-Branded" products, services, and technologies on a larger scale, fully leveraging CIFTIS's resource aggregation effect. A dedicated area was also set up for the China Service Trade Achievement Exhibition, highlighting China's progress in service trade development. Biokin Pharmaceutical took center stage in the Sichuan Pavilion, with its BL-B01D1 earning a coveted spot in the 2024 CIFTIS Achievement Exhibition. This made Biokin Pharmaceutical the only Sichuan-based company to receive such recognition.

BL-B01D1 is the world's first EGFR×HER3-targeting bispecific antibody-drug conjugate (ADC) to enter clinical trials. The BL-B01D1 project has established a global strategic partnership with BMS, a world-renowned pharmaceutical company, in a deal valued at $8.4 billion. This collaboration has set a new record for the largest global strategic licensing transaction in the ADC field, exemplifying China's pharmaceutical and healthcare service trade's advancement into the international industrial chain.